

# Robin L Jones

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9179431/robin-l-jones-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

353  
papers

11,468  
citations

55  
h-index

97  
g-index

412  
ext. papers

14,528  
ext. citations

5  
avg, IF

6.38  
L-index

#	Paper	IF	Citations
353	Efficacy of Eribulin in Soft Tissue Sarcomas.. <i>Frontiers in Pharmacology</i> , <b>2022</b> , 13, 869754	5.6	0
352	Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2101829	2.2	1
351	Machine learning for rhabdomyosarcoma histopathology.. <i>Modern Pathology</i> , <b>2022</b> ,	9.8	3
350	SMARCA4-Deficient Thoracic Sarcoma. <i>International Journal of Surgical Pathology</i> , <b>2021</b> , 29, 640-641	1.2	0
349	Dedifferentiated chondrosarcoma: current standards of care. <i>Future Oncology</i> , <b>2021</b> , 17, 4983-4991	3.6	
348	Risk factors for the development of local recurrence in extremity soft-tissue sarcoma. <i>Expert Review of Anticancer Therapy</i> , <b>2021</b> , 1-13	3.5	1
347	Olaratumab-induced Biomarker Modulation in Sarcomas-Response. <i>Molecular Cancer Therapeutics</i> , <b>2021</b> , 20, 2094	6.1	
346	The perplexing role of immuno-oncology drugs in osteosarcoma. <i>Journal of Bone Oncology</i> , <b>2021</b> , 31, 100400	4.5	1
345	Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study.. <i>Nature Cancer</i> , <b>2021</b> , 2, 1321-1337	15.4	17
344	Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas. <i>Npj Precision Oncology</i> , <b>2021</b> , 5, 17	9.8	6
343	Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature. <i>Cancer Medicine</i> , <b>2021</b> , 10, 2645-2659	4.8	8
342	Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. <i>European Journal of Cancer</i> , <b>2021</b> , 145, 132-142	7.5	24
341	Extraskeletal osteosarcomas: current update. <i>Future Oncology</i> , <b>2021</b> , 17, 825-835	3.6	2
340	Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. <i>Cancer</i> , <b>2021</b> , 127, 2934-2942	6.4	11
339	Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group. <i>Annals of Surgical Oncology</i> , <b>2021</b> , 28, 7873-7888	3.1	15
338	Intra-patient dose escalation (IPDE) of ripretinib after disease progression in patients with advanced gastrointestinal stromal tumor (GIST): Analyses from the phase 3 INVICTUS study.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 11536-11536	2.2	
337	IL-15 mediated expansion of rare durable memory T cells following adoptive cellular therapy <b>2021</b> , 9,		1

336	Phase (Ph) 1b/2 evaluation of olaratumab in combination with gemcitabine and docetaxel in advanced soft tissue sarcoma (STS).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 11517-11517	2.2	0
335	Next-generation sequencing for the management of sarcomas with no known driver mutations. <i>Current Opinion in Oncology</i> , <b>2021</b> , 33, 315-322	4.2	2
334	Managing the risk of toxicity in the treatment of elderly patients with soft tissue sarcomas. <i>Expert Opinion on Drug Safety</i> , <b>2021</b> , 20, 903-913	4.1	0
333	Clinical management and outcomes of primary ovarian leiomyosarcoma - Experience from a sarcoma specialist unit. <i>Gynecologic Oncology Reports</i> , <b>2021</b> , 36, 100737	1.3	3
332	Results of the phase 1b soft-tissue sarcoma (STS) portion of the global randomized, double-blind, placebo-controlled study of tazemetostat (TAZ) plus doxorubicin (DOX) as frontline therapy for advanced epithelioid sarcoma (ES).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 11563-11563	2.2	
331	Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer. <i>Cancer Medicine</i> , <b>2021</b> , 10, 3565-3574	4.8	0
330	Proteomic profiling of soft tissue sarcomas with SWATH mass spectrometry. <i>Journal of Proteomics</i> , <b>2021</b> , 241, 104236	3.9	4
329	Articulatory Correlates of Stress Pattern Disturbances in Talkers With Dysarthria. <i>Journal of Speech, Language, and Hearing Research</i> , <b>2021</b> , 64, 2287-2300	2.8	
328	The Evaluation of Health-Related Quality of Life Issues Experienced by Patients with Desmoid-Type Fibromatosis (The QUALIFIED Study)-A Protocol for an International Cohort Study. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
327	What Matters to Us: Impact of Telemedicine During the Pandemic in the Care of Patients With Sarcoma Across Scotland. <i>JCO Global Oncology</i> , <b>2021</b> , 7, 1067-1073	3.7	0
326	The evolving management of epithelioid sarcoma. <i>European Journal of Cancer Care</i> , <b>2021</b> , 30, e13489	2.4	0
325	Oncological Outcome After Diagnostic Biopsies in Gastrointestinal Stromal Tumors: A Retrospective Cohort Study. <i>Annals of Surgery</i> , <b>2021</b> , 274, e1093-e1098	7.8	4
324	-Positive Fibroblastic Tumor. <i>International Journal of Surgical Pathology</i> , <b>2021</b> , 29, 179-181	1.2	2
323	Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma. <i>Molecular Cancer Therapeutics</i> , <b>2021</b> , 20, 132-141	6.1	7
322	Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors. <i>Oncologist</i> , <b>2021</b> , 26, e622-e631	5.7	11
321	Gynecological Sarcomas: Molecular Characteristics, Behavior, and Histology-Driven Therapy. <i>International Journal of Surgical Pathology</i> , <b>2021</b> , 29, 4-20	1.2	3
320	Current Reality of Treating Advanced Soft Tissue Sarcoma as Illustrated by Case Studies. <i>Oncology</i> , <b>2021</b> , 99 Suppl 1, 8-16	3.6	
319	The role of [ <sup>67</sup> Ga]Ga-DOTATATE PET/CT in wild-type KIT/PDGFRα gastrointestinal stromal tumours (GIST). <i>EJNMMI Research</i> , <b>2021</b> , 11, 5	3.6	2

318	Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patients-A Position Paper from the National Leiomyosarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN). <i>Cancers</i> , <b>2021</b> , 13,	6.6	4
317	Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy. <i>Oncologist</i> , <b>2021</b> , 26, e639-e649	5.7	11
316	Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 3861-3866	12.9	2
315	Pharmacotherapy for liposarcoma: current and emerging synthetic treatments. <i>Future Oncology</i> , <b>2021</b> , 17, 2659-2670	3.6	0
314	Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European study. <i>European Journal of Surgical Oncology</i> , <b>2021</b> , 47, 2173-2181	3.6	1
313	Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study. <i>Oncologist</i> , <b>2021</b> , 26, e2053-e2060	5.7	3
312	Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma. <i>Future Oncology</i> , <b>2021</b> , 17, 2923-2939	3.6	5
311	Ripretinib inpatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour. <i>European Journal of Cancer</i> , <b>2021</b> , 155, 236-244	7.5	2
310	Desmoid fibromatosis: is the current picture changing?. <i>Future Oncology</i> , <b>2021</b> , 17, 3397-3408	3.6	1
309	Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous Mutations in the Phase III INVICTUS Study. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 6333-6342	12.9	4
308	Solitary fibrous tumor: molecular hallmarks and treatment for a rare sarcoma. <i>Future Oncology</i> , <b>2021</b> , 17, 3627-3636	3.6	2
307	Gastrointestinal leiomyosarcoma demonstrate a predilection for distant recurrence and poor response to systemic treatments. <i>European Journal of Surgical Oncology</i> , <b>2021</b> , 47, 2595-2601	3.6	0
306	Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3128-3139	2.2	12
305	Future Directions in the Treatment of Osteosarcoma. <i>Cells</i> , <b>2021</b> , 10,	7.9	37
304	The Extracellular Matrix in Soft Tissue Sarcomas: Pathobiology and Cellular Signalling.. <i>Frontiers in Cell and Developmental Biology</i> , <b>2021</b> , 9, 763640	5.7	0
303	Imaging features of primary sites and metastatic patterns of angiosarcoma.. <i>Insights Into Imaging</i> , <b>2021</b> , 12, 189	5.6	0
302	1623MO Ripretinib intra-patient dose escalation (IPDE) following disease progression provides clinically meaningful progression-free survival (PFS) in gastrointestinal stromal tumor (GIST) in phase I study. <i>Annals of Oncology</i> , <b>2020</b> , 31, S974-S975	10.3	3
301	A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1. <i>OncImmunity</i> , <b>2020</b> , 9, 1847846	7.2	7

300	Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland. <i>Clinical Sarcoma Research</i> , <b>2020</b> , 10, 9	2.5	4
299	Metastatic Soft Tissue Sarcomas in Adolescents and Young Adults: A Specialist Center Experience. <i>Journal of Adolescent and Young Adult Oncology</i> , <b>2020</b> , 9, 628-638	2.2	3
298	Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung. <i>Sarcoma</i> , <b>2020</b> , 2020, 7935475	2.1	9
297	Revolutions in treatment options in gastrointestinal stromal tumours (GISTs): the latest updates. <i>Current Treatment Options in Oncology</i> , <b>2020</b> , 21, 55	5.4	23
296	Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 923-934	21.7	102
295	Robotic surgery for gastric gastrointestinal stromal tumors: A single center case series. <i>Journal of Surgical Oncology</i> , <b>2020</b> , 122, 691	2.8	5
294	Tropomyosin receptor kinase inhibitors in the management of sarcomas. <i>Current Opinion in Oncology</i> , <b>2020</b> , 32, 307-313	4.2	4
293	Health-related quality Of Life n patients with advanced Soft Tissue sarcomas treated with Chemotherapy (The HOLISTIC study): protocol for an international observational cohort study. <i>BMJ Open</i> , <b>2020</b> , 10, e035171	3	4
292	Familial adenomatosis polyposis-related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis. <i>ESMO Open</i> , <b>2020</b> , 5,	6	5
291	Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study. <i>British Journal of Cancer</i> , <b>2020</b> , 122, 1158-1165	8.7	10
290	Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 935-946	21.7	101
289	Superficial CD34-Positive Fibroblastic Tumor. <i>International Journal of Surgical Pathology</i> , <b>2020</b> , 28, 879-881	2.1	3
288	Rib destruction by epithelioid tumour in a young man. <i>Journal of Clinical Pathology</i> , <b>2020</b> , 73, e2	3.9	0
287	Low-grade Fibromyxoid Sarcoma: Treatment Outcomes and Efficacy of Chemotherapy. <i>In Vivo</i> , <b>2020</b> , 34, 239-245	2.3	13
286	Is the IDH Mutation a Good Target for Chondrosarcoma Treatment?. <i>Current Molecular Biology Reports</i> , <b>2020</b> , 6, 1-9	2	11
285	Durable tumor regression in highly refractory metastatic [wild-type GIST following treatment with nivolumab. <i>Oncolmmunology</i> , <b>2020</b> , 9, 1710064	7.2	3
284	Different approaches to advanced soft tissue sarcomas depending on treatment line, goal of therapy and histological subtype. <i>Expert Review of Anticancer Therapy</i> , <b>2020</b> , 20, 15-28	3.5	4
283	Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 323, 1266-1276	27.4	91

282	Histiocyte predominant myocarditis resulting from the addition of interferon gamma to cyclophosphamide-based lymphodepletion for adoptive cellular therapy <b>2020</b> , 8,		4
281	The sacral chordoma margin. <i>European Journal of Surgical Oncology</i> , <b>2020</b> , 46, 1415-1422	3.6	16
280	A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin $\pm$ ifosfamide following surgery or in metastatic first line treatment (EORTC62113). <i>International Journal of Gynecological Cancer</i> , <b>2020</b> , 30, 1633-1637	3.5	2
279	Quality of life (QoL) and self-reported function with ripretinib in 4 <sup>th</sup> -line therapy for patients with gastrointestinal stromal tumors (GIST): Analyses from INVICTUS.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 11535-11535	2.2	4
278	Safety profile of ripretinib, including impact of alopecia, and Palmar-Plantar Erythrodysesthesia Syndrome (PPES) on patient-reported outcomes (PROs), in 4 <sup>th</sup> -line advanced gastrointestinal stromal tumors (GIST): Analyses from INVICTUS.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 11539-11539	2.2	3
277	Efficacy, safety, and immune priming effect of tazemetostat in patients with epithelioid sarcoma.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 11564-11564	2.2	1
276	The route to diagnosis of sarcoma patients: Results from an interview study in the Netherlands and the United Kingdom. <i>PLoS ONE</i> , <b>2020</b> , 15, e0243439	3.7	1
275	Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors. <i>Future Oncology</i> , <b>2020</b> , 16, 1639-1646	3.6	4
274	The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. <i>European Journal of Cancer</i> , <b>2020</b> , 127, 96-107	7.5	108
273	Primary ilioacaval leiomyosarcomas: The path beyond surgery. <i>European Journal of Surgical Oncology</i> , <b>2020</b> , 46, 893-897	3.6	4
272	Proteomic research in sarcomas - current status and future opportunities. <i>Seminars in Cancer Biology</i> , <b>2020</b> , 61, 56-70	12.7	22
271	Toxicity management of regorafenib in patients with gastro-intestinal stromal tumour (GIST) in a tertiary cancer centre. <i>Clinical Sarcoma Research</i> , <b>2020</b> , 10, 1	2.5	8
270	Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study. <i>ESMO Open</i> , <b>2020</b> , 5,	6	8
269	Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. <i>Annals of Oncology</i> , <b>2020</b> , 31, 1506-1517	10.3	39
268	Diagnostic Differences in Expert Second-Opinion Consultation Cases at a Tertiary Sarcoma Center. <i>Sarcoma</i> , <b>2020</b> , 2020, 9810170	3.1	2
267	A Timely Oral Option: Single-Agent Vinorelbine in Desmoid Tumors. <i>Oncologist</i> , <b>2020</b> , 25, e2013-e2016	5.7	5
266	Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. <i>Lancet Oncology</i> , <b>2020</b> , 21, 1423-1432	21.7	71
265	Telemedicine During the COVID-19 Pandemic: Impact on Care for Rare Cancers. <i>JCO Global Oncology</i> , <b>2020</b> , 6, 1046-1051	3.7	46

264	Defining the true impact of coronavirus disease 2019 in the at-risk population of patients with cancer. <i>European Journal of Cancer</i> , <b>2020</b> , 136, 99-106	7.5	23
263	Optimal Clinical Management and the Molecular Biology of Angiosarcomas. <i>Cancers</i> , <b>2020</b> , 12,	6.6	8
262	Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma: A Phase 1/2 Nonrandomized Clinical Trial. <i>JAMA Oncology</i> , <b>2020</b> , 6, 1778-1782	13.4	22
261	Epithelioid malignant peripheral nerve sheath tumor arising in schwannoma. <i>Rare Tumors</i> , <b>2020</b> , 12, 2036-2040	3.6	132095086
260	Paraneoplastic dermatomyositis associated with metastatic leiomyosarcoma of unknown primary. <i>Clinical Sarcoma Research</i> , <b>2020</b> , 10, 15	2.5	0
259	Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3294-3303	2.2	31
258	Health-Related Quality of Life and Experiences of Sarcoma Patients during the COVID-19 Pandemic. <i>Cancers</i> , <b>2020</b> , 12,	6.6	20
257	Efficacy of Gemcitabine-based Chemotherapy in Clear Cell Sarcoma of Soft Tissue. <i>Anticancer Research</i> , <b>2020</b> , 40, 7003-7007	2.3	1
256	Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy. <i>European Urology Focus</i> , <b>2020</b> , 6, 999-1005	5.1	3
255	Subgroup analysis of older patients treated within the randomized phase 3 doxorubicin versus doxorubicin plus evofosfamide (SARC021) trial. <i>Journal of Geriatric Oncology</i> , <b>2020</b> , 11, 463-469	3.6	4
254	Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. <i>Cancer</i> , <b>2020</b> , 126, 98-104	6.4	14
253	Embryonal and Alveolar Rhabdomyosarcoma in Adults: Real-Life Data From a Tertiary Sarcoma Centre. <i>Clinical Oncology</i> , <b>2020</b> , 32, e27-e35	2.8	7
252	Perineal mass in a 50-year-old man. <i>Journal of Clinical Pathology</i> , <b>2020</b> , 73, e5	3.9	0
251	The Emerging Role of Platelets in the Formation of the Micrometastatic Niche: Current Evidence and Future Perspectives. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 374	5.3	11
250	Outcome of Primary Desmoid Tumors at All Anatomic Locations Initially Managed with Active Surveillance. <i>Annals of Surgical Oncology</i> , <b>2019</b> , 26, 4699-4706	3.1	15
249	Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours. <i>European Journal of Cancer</i> , <b>2019</b> , 120, 132-139	7.5	12
248	The Role of Local Therapy in Multi-focal Epithelioid Haemangioendothelioma. <i>Anticancer Research</i> , <b>2019</b> , 39, 4891-4896	2.3	7
247	Sarcomas and old age: few options for such a large patient population. <i>Future Oncology</i> , <b>2019</b> , 15, 11-15	3.6	4

246	Treatment of Desmoid Tumors in 2019. <i>JAMA Oncology</i> , <b>2019</b> , 5, 567-568	13.4	19
245	Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma. <i>BMC Cancer</i> , <b>2019</b> , 19, 593	4.8	9
244	Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas). <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 5295-5300	12.9	38
243	First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 5808-5817	12.9	38
242	Systemic Interferon- $\gamma$ Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial. <i>Cancer Immunology Research</i> , <b>2019</b> , 7, 1237-1243	12.5	44
241	Pazopanib in advanced soft tissue sarcomas. <i>Signal Transduction and Targeted Therapy</i> , <b>2019</b> , 4, 16	2.1	32
240	Pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma. <i>Expert Opinion on Investigational Drugs</i> , <b>2019</b> , 28, 505-511	5.9	7
239	A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas. <i>Cancer</i> , <b>2019</b> , 125, 2445-2454	6.4	9
238	Aldoxorubicin in soft tissue sarcomas. <i>Future Oncology</i> , <b>2019</b> , 15, 1429-1435	3.6	8
237	Gemcitabine Re-challenge in Metastatic Soft Tissue Sarcomas: A Therapeutic Option for Selected Patients. <i>Anticancer Research</i> , <b>2019</b> , 39, 347-351	2.3	
236	The adequacy of tissue microarrays in the assessment of inter- and intra-tumoural heterogeneity of infiltrating lymphocyte burden in leiomyosarcoma. <i>Scientific Reports</i> , <b>2019</b> , 9, 14602	4.9	10
235	Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin. <i>Cancer</i> , <b>2019</b> , 125, 4435-4441	6.4	7
234	The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib. <i>Expert Review of Anticancer Therapy</i> , <b>2019</b> , 19, 971-991	3.5	18
233	Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients (pts) with epithelioid sarcoma (ES) (NCT02601950).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 11003-11003	2.2	33
232	ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, LBA3-LBA3	2.2	38
231	The SAINT: Initial results of a phase I/II study of safety/efficacy using safe amounts of ipilimumab, nivolumab, and trabectedin as first-line treatment of advanced soft tissue sarcoma.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 22-22	2.2	1
230	Adult soft tissue myoepithelial carcinoma: treatment outcomes and efficacy of chemotherapy. <i>Medical Oncology</i> , <b>2019</b> , 37, 13	3.7	9
229	Negative phase III trials announce the need for biomarkers in sarcoma. <i>European Journal of Cancer</i> , <b>2019</b> , 123, 81-82	7.5	1



228	Imaging Soft-tissue Sarcomas of the Head and Neck: A Tertiary Soft-tissue Sarcoma Unit Experience. <i>Anticancer Research</i> , <b>2019</b> , 39, 6223-6230	2.3	1
227	Exposure-response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2019</b> , 83, 191-199	3.5	9
226	Desmoid fibromatosis through the patientsPeyes: time to change the focus and organisation of care?. <i>Supportive Care in Cancer</i> , <b>2019</b> , 27, 965-980	3.9	9
225	Ending 40 years of silence: Rationale for a new staging system for soft tissue sarcoma of the head and neck. <i>Clinical and Translational Radiation Oncology</i> , <b>2019</b> , 15, 13-19	4.6	3
224	Olaratumab in soft tissue sarcoma - Current status and future perspectives. <i>European Journal of Cancer</i> , <b>2018</b> , 92, 33-39	7.5	13
223	Endometrial Stromal Sarcoma With Hyalinizing Giant Rosettes, Mimicking Low-Grade Fibromyxoid Sarcoma. <i>International Journal of Surgical Pathology</i> , <b>2018</b> , 26, 525-527	1.2	1
222	Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series. <i>JAMA Oncology</i> , <b>2018</b> , 4, e180219	13.4	46
221	Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials. <i>Oncologist</i> , <b>2018</b> , 23, 1250-1259	5.7	18
220	The current landscape of early drug development for patients with sarcoma in the immunotherapy era. <i>Future Oncology</i> , <b>2018</b> , 14, 1197-1211	3.6	8
219	Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients. <i>Acta Oncologica</i> , <b>2018</b> , 57, 958-964	3.2	29
218	Successful Ifosfamide Rechallenge in Soft-Tissue Sarcoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2018</b> , 41, 147-151	2.7	13
217	Safety and Efficacy Outcomes of Embolization in Hepatic Sarcomas. <i>American Journal of Roentgenology</i> , <b>2018</b> , 210, 175-182	5.4	15
216	Pancreaticoduodenectomy for the Management of Pancreatic or Duodenal Metastases from Primary Sarcoma. <i>Anticancer Research</i> , <b>2018</b> , 38, 4041-4046	2.3	3
215	2018 ESMO Sarcoma and GIST Symposium: Rake-home messagesPin soft tissue sarcoma. <i>ESMO Open</i> , <b>2018</b> , 3, e000390	6	5
214	Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling. <i>Future Oncology</i> , <b>2018</b> , 14, 2663-2676	3.6	72
213	Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. <i>Annals of Oncology</i> , <b>2018</b> , 29, 1995-2002	10.3	22
212	Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma. <i>Medical Oncology</i> , <b>2018</b> , 35, 131	3.7	9
211	The Value of Neoadjuvant Chemotherapy in Localized High-Risk Soft-Tissue Sarcoma of the Extremities and Trunk. <i>JAMA Oncology</i> , <b>2018</b> , 4, 1167-1168	13.4	10

210	Effect of intratumoral (IT) injection of the toll-like receptor 4 (TLR4) agonist G100 on a clinical response and CD4 T-cell response locally and systemically.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 71-71	2.2	2
209	Clear Cell Sarcoma-like Tumor of the Gastrointestinal Tract: Clinical Outcome and Pathologic Features of a Molecularly Characterized Tertiary Center Case Series. <i>Anticancer Research</i> , <b>2018</b> , 38, 1479-1483	2.3	13
208	Gemcitabine re-challenge in metastatic soft tissue sarcoma: A therapeutic option for selected patients.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 11559-11559	2.2	
207	TAPPAS: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS11590-TPS11590	2.2	1
206	Lack of cardiac toxicity in patients treated with aldoxrubicin with doxorubicin equivalent doses beyond 1000mg/m2.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 11585-11585	2.2	1
205	Paediatric, adolescent, wild type, syndromic gastrointestinal stromal tumours (PAWS-GIST): Report from United Kingdom PAWS-GIST clinic.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e23519-e23519	2.2	
204	Detection of endoglin-expressing CTCs in patients enrolled in an adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e23570-e23570	2.2	
203	Optimising Cancer Vaccine Design in Sarcoma. <i>Cancers</i> , <b>2018</b> , 11,	6.6	78
202	Systemic therapy in retroperitoneal sarcoma management. <i>Journal of Surgical Oncology</i> , <b>2018</b> , 117, 87-92	2.8	8
201	Clinical and Molecular Spectrum of Liposarcoma. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 151-159	2.2	84
200	Perspectives on the evolving state of the art management of gastrointestinal stromal tumours. <i>Translational Gastroenterology and Hepatology</i> , <b>2018</b> , 3, 21	5.2	3
199	Systemic Anti-Cancer Therapy in Synovial Sarcoma: A Systematic Review. <i>Cancers</i> , <b>2018</b> , 10,	6.6	23
198	Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , <b>2018</b> , 29, iv79-iv95	10.3	223
197	Clinical Characteristics and efficacy of chemotherapy in sclerosing epithelioid fibrosarcoma. <i>Medical Oncology</i> , <b>2018</b> , 35, 138	3.7	14
196	Age-related sarcoma patient experience: results from a national survey in England. <i>BMC Cancer</i> , <b>2018</b> , 18, 991	4.8	18
195	Aggressive fibromatosis response to tamoxifen: lack of correlation between MRI and symptomatic response. <i>Clinical Sarcoma Research</i> , <b>2018</b> , 8, 13	2.5	19
194	Preserving quality of life as a key treatment goal in advanced soft tissue sarcomas. <i>Expert Review of Anticancer Therapy</i> , <b>2018</b> , 18, 1241-1248	3.5	2
193	Trends in Modern Phase 1 Oncology Trials. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 1189	59.2	3

192	Synovial Sarcoma of the Thyroid Gland, Diagnostic Pitfalls and Clinical Management. <i>Anticancer Research</i> , <b>2018</b> , 38, 5275-5282	2.3	4
191	Advances in the treatment of soft tissue sarcoma: focus on eribulin. <i>Cancer Management and Research</i> , <b>2018</b> , 10, 207-216	3.6	8
190	Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , <b>2018</b> , 29, iv68-iv78	10.3	207
189	Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , <b>2018</b> , 29, iv51-iv67	10.3	316
188	Quality of life and patientsPexpectations in soft tissue sarcoma. <i>Future Oncology</i> , <b>2018</b> , 14, 51-62	3.6	10
187	Acral myxoinflammatory fibroblastic sarcoma with hybrid features of hemosiderotic fibrolipomatous tumor occurring 10 years after renal transplantation. <i>Rare Tumors</i> , <b>2018</b> , 10, 2036361318782626	11.1	26
186	The spectrum of EWSR1-rearranged neoplasms at a tertiary sarcoma centre; assessing 772 tumour specimens and the value of current ancillary molecular diagnostic modalities. <i>British Journal of Cancer</i> , <b>2017</b> , 116, 669-678	8.7	36
185	Novel therapeutic approaches in chondrosarcoma. <i>Future Oncology</i> , <b>2017</b> , 13, 637-648	3.6	74
184	Phase III Soft Tissue Sarcoma Trials: Success or Failure?. <i>Current Treatment Options in Oncology</i> , <b>2017</b> , 18, 19	5.4	16
183	T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas. <i>Cancer</i> , <b>2017</b> , 123, 3291-3304	6.4	135
182	Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2017</b> , 164, 395-400	4.4	10
181	Eribulin in advanced liposarcoma and leiomyosarcoma. <i>Expert Review of Anticancer Therapy</i> , <b>2017</b> , 17, 717-723	3.5	8
180	Treatment of retroperitoneal sarcoma: current standards and new developments. <i>Current Opinion in Oncology</i> , <b>2017</b> , 29, 260-267	4.2	29
179	Pazopanib, a promising option for the treatment of aggressive fibromatosis. <i>Anti-Cancer Drugs</i> , <b>2017</b> , 28, 421-426	2.4	28
178	The Adequacy of Core Biopsy in the Assessment of Smooth Muscle Neoplasms of Soft Tissues: Implications for Treatment and Prognosis. <i>American Journal of Surgical Pathology</i> , <b>2017</b> , 41, 923-931	6.7	23
177	Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group. <i>Annals of Oncology</i> , <b>2017</b> , 28, 1230-1242	10.3	108
176	Advances in the Pathology and Molecular Biology of Sarcomas and the Impact on Treatment. <i>Clinical Oncology</i> , <b>2017</b> , 29, 471-480	2.8	4
175	Treatment of soft tissue sarcoma: a focus on earlier stages. <i>Future Oncology</i> , <b>2017</b> , 13, 13-21	3.6	12

174	Olaratumab for the treatment of soft-tissue sarcoma. <i>Future Oncology</i> , <b>2017</b> , 13, 2151-2157	3.6	
173	Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma. <i>Medical Oncology</i> , <b>2017</b> , 34, 167	3.7	26
172	SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors. <i>Sarcoma</i> , <b>2017</b> , 2017, 8685638	3.1	35
171	Radiation induced angiosarcoma of the breast: outcomes from a retrospective case series. <i>Clinical Sarcoma Research</i> , <b>2017</b> , 7, 15	2.5	24
170	Myoepithelial Carcinoma of the Paracecal Mesentery: Aggressive Behavior of a Rare Neoplasm at an Unusual Anatomic Site. <i>Rare Tumors</i> , <b>2017</b> , 9, 6504	1.1	2
169	Olaratumab: a platelet-derived growth factor receptor- $\beta$ -blocking antibody for the treatment of soft tissue sarcoma. <i>Clinical Pharmacology: Advances and Applications</i> , <b>2017</b> , 9, 159-164	1.5	3
168	Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3433-3439	2.2	77
167	Isolated limb perfusion for locally advanced angiosarcoma in extremities: A multi-centre study. <i>European Journal of Cancer</i> , <b>2017</b> , 85, 114-121	7.5	6
166	First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient. <i>Journal of Immunotherapy</i> , <b>2017</b> , 40, 302-306	5	38
165	Desmoplastic small round cell tumor: evaluation of reverse transcription-polymerase chain reaction and fluorescence in situ hybridization as ancillary molecular diagnostic techniques. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2017</b> , 471, 631-640	5.1	23
164	Sarcoma: Does histotype-tailored neoadjuvant therapy improve outcomes?. <i>Nature Reviews Clinical Oncology</i> , <b>2017</b> , 14, 589-590	19.4	1
163	Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 1089-1103	21.7	138
162	Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. <i>Gynecologic Oncology</i> , <b>2017</b> , 146, 531-537	4.9	35
161	An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma Patients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). <i>Annals of Oncology</i> , <b>2017</b> , 28, 2399-2408	10.3	174
160	Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. <i>Acta Oncologica</i> , <b>2017</b> , 56, 88-92	3.2	95
159	Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications. <i>Future Oncology</i> , <b>2017</b> , 13, 93-107	3.6	64
158	Promising novel therapeutic approaches in the management of gastrointestinal stromal tumors. <i>Future Oncology</i> , <b>2017</b> , 13, 185-194	3.6	6
157	The Current Landscape of Early Drug Development for Patients With Sarcoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2017</b> , 37, 807-810	7.1	3

156	Systemic Therapy in Metastatic or Unresectable Well-Differentiated/Dedifferentiated Liposarcoma. <i>Frontiers in Oncology</i> , <b>2017</b> , 7, 292	5.3	22
155	Abstract 2947: Intratumoral injection of the toll-like receptor 4 agonist G100 induces a T-cell response in the soft tissue sarcoma microenvironment <b>2017</b> ,		3
154	Clinical activity of BLU-285 in advanced gastrointestinal stromal tumor (GIST).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 11011-11011	2.2	15
153	Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with INI1 negative epithelioid sarcoma (NCT02601950).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 11058-11058	2.2	17
152	Anthracycline, gemcitabine, and pazopanib in epithelioid sarcoma: Results of a retrospective multi-institutional case series.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 11065-11065	2.2	2
151	A randomized, double-blind, placebo-controlled, phase III study of crenolanib in advanced or metastatic GIST patients bearing a D842V mutation in PDGFRA: The CrenoGIST study.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS11080-TPS11080	2.2	9
150	Tappas: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (AAS).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS11081-TPS11081 <sup>2,2</sup>	2.2	4
149	Olaratumab for the treatment of soft tissue sarcoma. <i>Drugs of Today</i> , <b>2017</b> , 53, 247-255	2.5	3
148	Soft Tissue Sarcoma of the Head and Neck <b>2017</b> , 499-505		3
147	Neoadjuvant chemotherapy in localised soft-tissue sarcomas: where do we go from here?. <i>Lancet Oncology</i> , <b>2017</b> , 18, 706-707	21.7	4
146	Correlation of T-cell infiltration and clonality with PD-L1 expression in soft tissue sarcomas.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 23-23	2.2	
145	Does MGMT (O6-methylguanineDNA methyltransferase) have a role in metastatic Ewing sarcoma (ES) patients (pts) undergoing temozolomide (TMZ) and irinotecan (IRI)?. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 11030-11030	2.2	
144	Safety and efficacy of trabectedin when administered in the inpatient vs. outpatient setting in a subset analysis of a phase III randomized clinical trial.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e22516-e22516 <sup>2,2</sup>	2.2	16
143	Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 786-93	2.2	466
142	Histology-Driven Therapy: The Importance of Diagnostic Accuracy in Guiding Systemic Therapy of Soft Tissue Tumors. <i>International Journal of Surgical Pathology</i> , <b>2016</b> , 24, 5-15	1.2	31
141	Desmoplastic Small Round Cell Tumor: Pathology, Genetics, and Potential Therapeutic Strategies. <i>International Journal of Surgical Pathology</i> , <b>2016</b> , 24, 672-684	1.2	40
140	PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3898-3905	2.2	107
139	Rare Aggressive Behavior of -Amplified Retroperitoneal Dedifferentiated Liposarcoma, with Brain, Lung and Subcutaneous Metastases. <i>Rare Tumors</i> , <b>2016</b> , 8, 6282	1.1	4

138	Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. <i>Lancet, The</i> , <b>2016</b> , 388, 488-97	4.0	428
137	Treatment of resectable intrathoracic sarcomas: a single institution experience over twenty years. <i>Journal of Radiation Oncology</i> , <b>2016</b> , 5, 169-177	0.7	3
136	The Current Status of Solitary Fibrous Tumor: Diagnostic Features, Variants, and Genetics. <i>International Journal of Surgical Pathology</i> , <b>2016</b> , 24, 281-92	1.2	124
135	p.(L576P) -KIT mutation in GIST: Favorable prognosis and sensitive to imatinib?. <i>Cancer Biology and Therapy</i> , <b>2016</b> , 17, 543-5	4.6	6
134	Phosphoproteomics in translational research: a sarcoma perspective. <i>Annals of Oncology</i> , <b>2016</b> , 27, 787-94	10.3	21
133	Treatment of advanced soft tissue sarcoma: efficacy and safety of trabectedin, a multitarget agent, and update on other systemic therapeutic options. <i>Expert Review of Clinical Pharmacology</i> , <b>2016</b> , 9, 501-312	3.8	3
132	Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) recommendations for pathological examination and reporting. <i>European Journal of Cancer</i> , <b>2016</b> , 53, 84-95	7.5	68
131	The state of Illinois obstetric hemorrhage project: pre-project and post-training examination scores. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2016</b> , 29, 845-9	2	8
130	Patient-reported outcomes from randomized, phase-3 study of trabectedin (T) vs. dacarbazine (D) in advanced leiomyosarcoma (LMS) or liposarcoma (LPS).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 11061-11061	11.2	4
129	Single-agent LV305 to induce anti-tumor immune and clinical responses in patients with advanced or metastatic sarcoma and other cancers expressing NY-ESO-1.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3093-3093	2.2	1
128	Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas. <i>Indian Journal of Medical and Paediatric Oncology</i> , <b>2016</b> , 37, 125-30	0.2	2
127	Using G100 (Glucopyranosyl Lipid A) to transform the sarcoma tumor immune microenvironment.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 11017-11017	2.2	
126	Temozolamide and irinotecan in metastatic Ewing sarcoma: An Italian Sarcoma Group and Royal Marsden Hospital join study.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 11033-11033	2.2	
125	The Imaging and Pathological Features of Metastatic Leiomyosarcoma in the Gallbladder. <i>Rare Tumors</i> , <b>2016</b> , 8, 6618	1.1	2
124	Soft Tissue Myoepithelial Carcinoma Metastatic to the Cecum: Highlighting an Unusual Metastatic Pattern and the Need for Diagnostic Awareness. <i>Rare Tumors</i> , <b>2016</b> , 8, 6086	1.1	1
123	Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin. <i>Cancer Management and Research</i> , <b>2016</b> , 8, 95-104	3.6	11
122	A Phase I/II Clinical Trial of Belinostat (PXD101) in Combination with Doxorubicin in Patients with Soft Tissue Sarcomas. <i>Sarcoma</i> , <b>2016</b> , 2016, 2090271	3.1	21
121	Targeting gastrointestinal stromal tumors: the role of regorafenib. <i>OncoTargets and Therapy</i> , <b>2016</b> , 9, 3009-16	4.4	4

120	Dedifferentiated Liposarcoma: Updates on Morphology, Genetics, and Therapeutic Strategies. <i>Advances in Anatomic Pathology</i> , <b>2016</b> , 23, 30-40	5.1	72
119	Epithelioid Sarcoma: Diagnostic Features and Genetics. <i>Advances in Anatomic Pathology</i> , <b>2016</b> , 23, 41-9	5.1	59
118	Cardiac safety and toxicity minimization of regorafenib treatment. <i>Colorectal Cancer</i> , <b>2016</b> , 5, 1-3	0.8	0
117	Dear John Hunter. <i>BMJ, The</i> , <b>2016</b> , 355, i6515	5.9	
116	Drug repositioning in sarcomas and other rare tumors. <i>EBioMedicine</i> , <b>2016</b> , 6, 4-5	8.8	2
115	Endosialin expression in soft tissue sarcoma as a potential marker of undifferentiated mesenchymal cells. <i>British Journal of Cancer</i> , <b>2016</b> , 115, 473-9	8.7	13
114	Dermatofibrosarcoma protuberans: pathology, genetics, and potential therapeutic strategies. <i>Annals of Diagnostic Pathology</i> , <b>2016</b> , 25, 64-71	2.2	87
113	Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone. <i>Clinical Sarcoma Research</i> , <b>2016</b> , 6, 15	2.5	64
112	Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach from the Trans-Atlantic RPS Working Group. <i>Annals of Surgical Oncology</i> , <b>2016</b> , 23, 3531-3540	3.1	82
111	Cardio-oncology: a special focus issue from Future Oncology. <i>Future Oncology</i> , <b>2015</b> , 11, 1993-4	3.6	
110	Cardio-oncology: an ongoing evolution. <i>Future Oncology</i> , <b>2015</b> , 11, 2059-66	3.6	10
109	Redefining the standard of care in metastatic leiomyosarcoma. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 360-2	21.7	5
108	Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 693-700	12.9	75
107	A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma. <i>Clinical Sarcoma Research</i> , <b>2015</b> , 5, 13	2.5	38
106	Treatment of chest wall sarcomas: a single-institution experience over 20 years. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2015</b> , 38, 80-6	2.7	15
105	Quality of life measures in soft tissue sarcoma. <i>Expert Review of Anticancer Therapy</i> , <b>2015</b> , 15, 95-100	3.5	14
104	Current and advancing systemic treatment options for soft tissue sarcomas. <i>Expert Opinion on Pharmacotherapy</i> , <b>2015</b> , 16, 2023-37	4	0
103	A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2015</b> , 76, 777-84	3.5	14

102	Clinical trial design methodologies for advanced sarcoma therapy. <i>Clinical Research and Regulatory Affairs</i> , <b>2015</b> , 32, 70-73		
101	The effect of surgery with radiation on pelvic Ewing sarcoma survival. <i>Journal of Surgical Oncology</i> , <b>2015</b> , 112, 861-5	2.8	13
100	Synovial sarcoma diagnosis and management in the era of targeted therapies. <i>Current Opinion in Oncology</i> , <b>2015</b> , 27, 316-22	4.2	23
99	Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing Sarcoma. <i>Rare Tumors</i> , <b>2015</b> , 7, 5992	1.1	24
98	Trabectedin in soft tissue sarcomas. <i>Marine Drugs</i> , <b>2015</b> , 13, 974-83	6	10
97	Epithelioid Sarcoma: Opportunities for Biology-Driven Targeted Therapy. <i>Frontiers in Oncology</i> , <b>2015</b> , 5, 186	5.3	24
96	Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy. <i>Annals of Oncology</i> , <b>2015</b> , 26, 75-80	10.3	72
95	A randomized phase Ib/II study evaluating the safety and efficacy of olaratumab (IMC-3G3), a human anti-platelet-derived growth factor $\beta$ (PDGFR $\beta$ ) monoclonal antibody, with or without doxorubicin (Dox), in advanced soft tissue sarcoma (STS).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 10501-10501	2.2	11
94	A phase I/II clinical trial of belinostat (PXD101) in combination with doxorubicin in patients with soft tissue sarcomas (STS).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 10516-10516	2.2	3
93	Phase I, first-in-human trial of LV305 in patients with advanced or metastatic cancer expressing NY-ESO-1.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3021-3021	2.2	7
92	Dermatofibrosarcoma protuberans: from translocation to targeted therapy. <i>Cancer Biology and Medicine</i> , <b>2015</b> , 12, 375-84	5.2	34
91	A Phase II multicenter, open-label, clinical and pharmacokinetic trial of PM00104 in patients with advanced Ewing Family of Tumors. <i>Investigational New Drugs</i> , <b>2014</b> , 32, 171-7	4.3	9
90	Myxoid Liposarcomas Demonstrate a Profound Response to Neoadjuvant Radiation Therapy: An MRI-Based Volumetric Analysis and Pathological Correlation. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2014</b> , 90, S756-S757	4	3
89	A contemporary large single-institution evaluation of resected retroperitoneal sarcoma. <i>Annals of Surgical Oncology</i> , <b>2014</b> , 21, 2150-8	3.1	41
88	Management and outcome of metastatic clear cell sarcoma. <i>European Journal of Surgical Oncology</i> , <b>2014</b> , 40, 1383	3.6	2
87	Molecular profiling of soft tissue sarcomas using next-generation sequencing: a pilot study toward precision therapeutics. <i>Human Pathology</i> , <b>2014</b> , 45, 1563-71	3.7	36
86	PM00104 (Zalypsis $\square$ ): a marine derived alkylating agent. <i>Molecules</i> , <b>2014</b> , 19, 12328-35	4.8	19
85	Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells <b>2014</b> , 2, 36		45



84	Success is not final and failure is not fatal. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3449-50	2.2	
83	Analysis of clinical prognostic factors for adult patients with head and neck sarcomas. <i>Otolaryngology - Head and Neck Surgery</i> , <b>2014</b> , 151, 976-83	5.5	18
82	The multidisciplinary management of giant cell tumor of bone. <i>Expert Review of Anticancer Therapy</i> , <b>2014</b> , 14, 783-90	3.5	9
81	Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. <i>Cell Reports</i> , <b>2014</b> , 6, 514-27	10.6	194
80	Systemic therapy in advanced uterine adenosarcoma with sarcomatous overgrowth. <i>Gynecologic Oncology</i> , <b>2014</b> , 132, 513	4.9	4
79	Trivalent ganglioside vaccine and immunologic adjuvant versus adjuvant alone in metastatic sarcoma patients rendered disease-free by surgery: A randomized phase 2 trial.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 10520-10520	2.2	11
78	Gemcitabine (G) and docetaxel (D) in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 10541-10541	2.2	1
77	Delayed development of a rhabdomyosarcoma following radiation for a spinal cord glioma. <i>Journal of Neuro-Oncology</i> , <b>2013</b> , 112, 115-8	4.8	3
76	Clinical benefit of trabectedin in uterine adenosarcoma. <i>Medical Oncology</i> , <b>2013</b> , 30, 501	3.7	15
75	The use of radiofrequency ablation in gastrointestinal stromal tumor. <i>Journal of Vascular and Interventional Radiology</i> , <b>2013</b> , 24, 751	2.4	
74	The evolution of systemic therapy in sarcoma. <i>Expert Review of Anticancer Therapy</i> , <b>2013</b> , 13, 211-23	3.5	23
73	An evaluation of [F-18]-fluorodeoxy-D-glucose positron emission tomography, bone scan, and bone marrow aspiration/biopsy as staging investigations in Ewing sarcoma. <i>Pediatric Blood and Cancer</i> , <b>2013</b> , 60, 1113-7	3	56
72	KIT signaling regulates primordial follicle formation in the neonatal mouse ovary. <i>Developmental Biology</i> , <b>2013</b> , 382, 186-97	3.1	43
71	Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , <b>2013</b> , 381, 295-302	4.0	908
70	Management of gastrointestinal stromal tumors. <i>Future Oncology</i> , <b>2013</b> , 9, 193-206	3.6	20
69	The efficacy of caffeine-potentiated chemotherapy in clear cell sarcoma. <i>International Journal of Clinical Oncology</i> , <b>2013</b> , 18, 356	4.2	
68	Diagnosis, prognosis, and management of leiomyosarcoma: recognition of anatomic variants. <i>Current Opinion in Oncology</i> , <b>2013</b> , 25, 384-9	4.2	32
67	Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 6902-11	12.9	52

66	Multiple liver abscess formation and primary gastrointestinal stromal tumor. <i>Rare Tumors</i> , <b>2013</b> , 5, e51	1.1	1
65	Clinical activity and tolerability of a 14-day infusional Ifosfamide schedule in soft-tissue sarcoma. <i>Sarcoma</i> , <b>2013</b> , 2013, 868973	3.1	41
64	Role of the antiapoptotic proteins BCL2 and MCL1 in the neonatal mouse ovary. <i>Biology of Reproduction</i> , <b>2013</b> , 88, 46	3.9	17
63	Bone cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2013</b> , 11, 688-723	7.3	70
62	Impact of (18)F-FDG PET/CT imaging in therapeutic decisions for malignant solitary fibrous tumor of the pelvis. <i>Clinical Nuclear Medicine</i> , <b>2013</b> , 38, 453-5	1.7	10
61	Targeted treatment for advanced soft tissue sarcoma: profile of pazopanib. <i>OncoTargets and Therapy</i> , <b>2013</b> , 6, 217-22	4.4	12
60	Conventional anthracycline-based chemotherapy has limited efficacy in solitary fibrous tumour. <i>Acta Oncologica</i> , <b>2012</b> , 51, 550-4	3.2	31
59	Molecular Classification of Breast Cancer. <i>Surgical Pathology Clinics</i> , <b>2012</b> , 5, 701-17	3.9	5
58	MDM2 inhibition in liposarcoma: a step in the right direction. <i>Lancet Oncology, The</i> , <b>2012</b> , 13, 1070-1	21.7	15
57	NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma. <i>Cancer</i> , <b>2012</b> , 118, 4564-70	6.4	86
56	Systemic therapy in primary angiosarcoma of the spleen. <i>Rare Tumors</i> , <b>2012</b> , 4, e55	1.1	19
55	Role of palliative chemotherapy in advanced epithelioid sarcoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2012</b> , 35, 351-7	2.7	39
54	Reducing maternal deaths through state maternal mortality review. <i>Journal of Women's Health</i> , <b>2012</b> , 21, 905-9	3	28
53	NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycytidine. <i>PLoS ONE</i> , <b>2012</b> , 7, e32165	3.7	45
52	Leiomyosarcomas of the inferior vena cava: diagnostic features on cross-sectional imaging. <i>Clinical Radiology</i> , <b>2011</b> , 66, 50-6	2.9	40
51	Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer. <i>European Journal of Cancer</i> , <b>2011</b> , 47, 138-50	7.5	117
50	Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study. <i>European Journal of Cancer</i> , <b>2011</b> , 47, 1006-12	7.5	77
49	Immune-based therapies for sarcoma. <i>Sarcoma</i> , <b>2011</b> , 2011, 438940	3.1	27

48	Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers. <i>Gynecologic Oncology</i> , <b>2011</b> , 123, 553-6	4.9	55
47	Clinical benefit of early phase clinical trial participation for advanced sarcoma patients. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2011</b> , 68, 423-9	3.5	12
46	Chemotherapy in clear cell sarcoma. <i>Medical Oncology</i> , <b>2011</b> , 28, 859-63	3.7	47
45	Advanced aggressive fibromatosis: Effective palliation with chemotherapy. <i>Acta Oncologica</i> , <b>2011</b> , 50, 455-61	3.2	46
44	Nuclear NF- $\kappa$ B/p65 expression and response to neoadjuvant chemotherapy in breast cancer. <i>Journal of Clinical Pathology</i> , <b>2011</b> , 64, 130-5	3.9	24
43	Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and Expectations. <i>Sarcoma</i> , <b>2011</b> , 2011, 402508	3.1	51
42	Fungal spinal cord compression in metastatic synovial sarcoma. <i>Acta Oncologica</i> , <b>2011</b> , 50, 158-9	3.2	3
41	Brivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): Biomarker and subset results of a phase II randomized discontinuation trial. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 10000-10000	2.2	9
40	Molecular subtypes and emerging therapeutic opportunities <b>2011</b> , 24-36		
39	Beyond triple-negative breast cancer: the need to define new subtypes. <i>Expert Review of Anticancer Therapy</i> , <b>2010</b> , 10, 1197-213	3.5	17
38	Clinical benefit of second-line palliative chemotherapy in advanced soft-tissue sarcoma. <i>Sarcoma</i> , <b>2010</b> , 2010, 264360	3.1	18
37	PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study. <i>Modern Pathology</i> , <b>2010</b> , 23, 1334-45	9.8	54
36	Radiofrequency ablation is a feasible therapeutic option in the multi modality management of sarcoma. <i>European Journal of Surgical Oncology</i> , <b>2010</b> , 36, 477-82	3.6	65
35	Atypical metastatic profile in Stewart-Treves syndrome. <i>Acta Oncologica</i> , <b>2010</b> , 49, 1388-90	3.2	
34	Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2010</b> , 16, 183-94	2.2	54
33	Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2010</b> , 119, 315-23	4.4	86
32	A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer. <i>British Journal of Cancer</i> , <b>2009</b> , 100, 305-10	8.7	32
31	A feasibility study of sequential doublet chemotherapy comprising carboplatin-doxorubicin and carboplatin-paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma. <i>Annals of Oncology</i> , <b>2009</b> , 20, 1787-93	10.3	8

30	Genomic profile of a secretory breast cancer with an ETV6-NTRK3 duplication. <i>Journal of Clinical Pathology</i> , <b>2009</b> , 62, 604-12	3.9	41
29	The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2009</b> , 116, 53-68	4.4	195
28	Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. <i>European Journal of Cancer</i> , <b>2009</b> , 45, 2930-4	7.5	94
27	Biomarkers and predictive factors of response to neoadjuvant treatment. <i>Breast Cancer Research</i> , <b>2009</b> , 11,	8.3	78
26	Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity. <i>Expert Review of Cardiovascular Therapy</i> , <b>2008</b> , 6, 1311-7	2.5	44
25	Outcome of high-dose cytarabine-based induction therapy followed by hematopoietic stem cell transplantation in acute myeloid leukemia: influence of karyotype. <i>Leukemia and Lymphoma</i> , <b>2008</b> , 49, 2284-90	1.9	2
24	Paclitaxel in the management of ovarian cancer. <i>Expert Review of Obstetrics and Gynecology</i> , <b>2008</b> , 3, 287-299		
23	Methylated NEUROD1 promoter is a marker for chemosensitivity in breast cancer. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 3494-502	12.9	33
22	Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis. <i>Breast Cancer Research and Treatment</i> , <b>2008</b> , 110, 245-56	4.4	57
21	Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. <i>Breast Cancer Research and Treatment</i> , <b>2008</b> , 111, 27-44	4.4	257
20	Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 90-101	12.9	180
19	Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2007</b> , 106, 181-9	4.4	94
18	MYC amplification in breast cancer: a chromogenic in situ hybridisation study. <i>Journal of Clinical Pathology</i> , <b>2007</b> , 60, 1017-23	3.9	50
17	Debulking hepatectomy for an unusual case of a grade 1 stage 1 granulosa cell tumour of the ovary with late metastases. <i>Oncology</i> , <b>2007</b> , 72, 143-4	3.6	5
16	Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. <i>Lancet Oncology</i> , <b>2007</b> , 8, 595-602	21.7	349
15	Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma. <i>British Journal of Cancer</i> , <b>2006</b> , 94, 358-62	8.7	79
14	Anthracycline cardiotoxicity. <i>Expert Opinion on Drug Safety</i> , <b>2006</b> , 5, 791-809	4.1	97
13	Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. <i>Expert Review of Anticancer Therapy</i> , <b>2006</b> , 6, 1249-69	3.5	61

12	Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response. <i>Lancet Oncology, The</i> , <b>2006</b> , 7, 869-74	21.7	53
11	Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue. <i>Modern Pathology</i> , <b>2006</b> , 19, 307-19	9.8	75
10	Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis. <i>Modern Pathology</i> , <b>2006</b> , 19, 999-1009	8.8	127
9	The development and application of imatinib. <i>Expert Opinion on Drug Safety</i> , <b>2005</b> , 4, 183-91	4.1	29
8	Use of endomyocardial biopsy to assess anthracycline-induced cardiotoxicity. <i>Lancet Oncology, The</i> , <b>2005</b> , 6, 67	21.7	7
7	Differential sensitivity of liposarcoma subtypes to chemotherapy. <i>European Journal of Cancer</i> , <b>2005</b> , 41, 2853-60	7.5	228
6	Tumour vaccine associated lymphadenopathy and false positive positron emission tomography scan changes. <i>British Journal of Radiology</i> , <b>2004</b> , 77, 74-5	3.4	29
5	Efficacy and safety of trastuzumab. <i>Expert Opinion on Drug Safety</i> , <b>2004</b> , 3, 317-27	4.1	16
4	Clinical and pathological absence of cardiotoxicity after liposomal doxorubicin. <i>Lancet Oncology, The</i> , <b>2004</b> , 5, 575-7	21.7	20
3	Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy?. <i>British Journal of Cancer</i> , <b>2003</b> , 89, 36-42	8.7	56
2	Clinical and molecular prognostic factors in patients with metastatic colorectal cancer treated with 5-fluorouracil-based chemotherapy. <i>Clinical Colorectal Cancer</i> , <b>2003</b> , 2, 235-8	3.8	
1	Adaptive immunity to SARS-CoV-2 in cancer patients: The CAPTURE study		2